New insights and guidelines for the management of CKD and diabetes10' education - May 31, 2022 - Prof. Johannes Mann, MD - Munich, Germany
Video navigation menu
- Three gigantic risk in DKD; What helps? 0:35
- KDIGO guidelines for treatment of patients with T2DM and CKD 3:09
- Evidence supporting role of GLP-1RA for kidney benefit 4:49
- Recent trial data with exendin-based GLP-1RA 7:47
This lecture by Johannes Mann was part of the EBAC-accredited symposium "Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA" held during the ERA 2022 congress.
Johannes Mann is professor of medicine at the University of Erlangen-Nürnberg, and affiliated at the KfH Kidney Center, Munich, Germany
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.
This educational activity is intended for an international audience of non-US and non-UK HCPs